The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.
IMPROVEMENT OF HPV L2 PEPTIDE IMMUNOGENICITY / Bolchi, Angelo; Müller, Martin; Ottonello, Simone; Pouyanfard, Somayeh; Spagnoli, Gloria. - (2017).
|Titolo:||IMPROVEMENT OF HPV L2 PEPTIDE IMMUNOGENICITY|
|Data di pubblicazione:||2017|
|Citazione:||IMPROVEMENT OF HPV L2 PEPTIDE IMMUNOGENICITY / Bolchi, Angelo; Müller, Martin; Ottonello, Simone; Pouyanfard, Somayeh; Spagnoli, Gloria. - (2017).|
|Appare nelle tipologie:||5.2 Domanda di brevetto|